Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cardiovascular Therapy
Phase III study examines ability of drug to slow atherosclerosis
February 27th, 2006
Researchers at the University of Rochester Medical Center have launched a phase III study to determine whether an experimental drug, rimonabant, can slow atherosclerosis, the fatty build-up in arteries that creates heart attack risk. In recent studies, rimonabant has been shown to decrease body weight, improve abnormal levels of blood sugars and fats (cholesterol), and to help willing patients quit smoking. Now researchers hope to add coronary artery disease (CAD), atherosclerosis within the arteries of the heart, to the list of maladies addressed. A decision on whether rimonabant is safe and effective and if so, for which uses, is expected from the U.S. Food & Drug...
Source: Pharma Business Week (2006-02-27)
|
